Fujifilm: Lutathera Injection Receives Marketing Authorization in Japan

2021-06-23 14:30:00

Fujifilm announced today that it has received marketing approval in Japan for Lutathera injection for the treatment of somatostatin receptor-positive neuroendocrine tumors.

Lutathera is a peptide receptor radionuclide therapy (PRRT), a subclass of radioligand therapy (RLT). Lutathera injection is the first PRRT drug in Japan.

Biomedicine Lutathera fujifilm

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Huawei's Automotive BU spin-off is in the countdown, and old employees are expected to receive extra compensation when they transfer to other companies? Insider: I haven't heard of it.
                            2024-12-27

                                    Mao Yinian, Vice President of Meituan: Meituan has invested in several robot companies including Yushu and Galaxy General
                            2024-12-27

                                    A-share SMIC rose more than 5%
                            2024-12-27

                                    Meituan Vice President Mao Yinian: Meituan has obtained Dubai drone delivery commercial operation qualification
                            2024-12-27

                                    Henan Provincial Development and Reform Commission held a symposium on the development of new energy vehicle industry
                            2024-12-27